VL-2511 / VeGen Labs - LARVOL DELTA

Hyderabad-based VeGen Bio has partnered with Bharat Biotech’s CRDMO-arm Nucelion Therapeutics to advance its dual-target myeloma CAR-T (The Economic Times) - "VL-2511 is a first-in-class dual autologous CAR-T therapy for multiple myeloma which simultaneously targets BCMA and CD19 (type of proteins). Under the agreement, the contract researcher will advance the drug in a Phase 1/2 trial in India. VeGen Bio expects to commercialize it in 2028 and Nucelion, will also serve as the company’s manufacturing partner for the drug."

Commercial • Licensing / partnership • New P1/2 trial • Multiple Myeloma